| 前收市價 | 6.74 |
| 開市 | 6.78 |
| 買盤 | 6.78 x 1800 |
| 賣出價 | 6.81 x 900 |
| 今日波幅 | 6.65 - 6.81 |
| 52 週波幅 | 3.06 - 6.81 |
| 成交量 | |
| 平均成交量 | 2,516,672 |
| 市值 | 1.578B |
| Beta 值 (5 年，每月) | 0.43 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.13 |
| 業績公佈日 | 2024年5月09日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 8.38 |
ZacksAdma Biologics (ADMA) Rises Higher Than Market: Key Facts
Adma Biologics (ADMA) reachead $6.74 at the closing of the latest trading day, reflecting a +1.05% change compared to its last close.
ZacksAdma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
ZacksWhat's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
